Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Sinopharm Group Co ( (HK:1099) ).
Sinopharm Group Co., Ltd. has released the unaudited financial data for its subsidiary, China National Medical Device Co., Ltd. (CNMDC), for the first half of 2025. The report shows a slight decline in revenue and operating profit compared to the previous year, with revenue down by 1.48% and operating profit by 8.28%. However, total comprehensive income attributable to the parent company saw a marginal increase of 1.02%. Notably, the net cash flow from operating activities improved significantly, reducing the deficit by 67.88%. The company’s total assets and equity attributable to owners also saw growth, indicating a stable financial position despite the challenges. This financial update may impact stakeholders’ perceptions of CNMDC’s market positioning and operational efficiency.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$21.50 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
More about Sinopharm Group Co
Sinopharm Group Co., Ltd. is a major player in the healthcare industry, primarily focusing on the distribution and retail of pharmaceuticals and medical devices. The company operates through various subsidiaries, including China National Medical Device Co., Ltd. (CNMDC), which plays a significant role in the medical device sector.
Average Trading Volume: 6,075,952
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$61.38B
Learn more about 1099 stock on TipRanks’ Stock Analysis page.